Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 08/25 10:00:00 pm
96.38 USD   -0.34%
08/22 S&P 500 MOVERS : Mro, regn
08/15 VERTEX PHARMACE : Provides Update on Ongoing Phase 3 Program for VX-..
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CEST

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
08/22 S&P 500 MOVERS : Mro, regn
08/15 VERTEX PHARMACEUTICALS INCORPORATED : Provides Update on Ongoing Phase 3 Program..
08/11 OPHTHOTECH : Announces Election of Ian F. Smith, Vertex Executive Vice President..
08/04 VERTEX PHARMACEUTICALS : Trek Therapeutics Acquires Two Antiviral Inhibitors Fro..
08/01 VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
07/28 VERTEX PHARMACEUTICALS : Researchers Submit Patent Application, "Processes for P..
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
07/27 VERTEX PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/23 Who's Next After Medivation?
08/19 Bayer/CRISPR Therapeutics joint venture Casebia Therapeutics establishes oper..
08/17 Prospects of cystic fibrosis candidate PTI-428 has Proteostasis on a run; sha..
08/17 Vertex Weathers Miss As Bigger Catalysts Loom
08/15 After Hours Gainers / Losers
Advertisement
Financials ($)
Sales 2016 1 769 M
EBIT 2016 271 M
Net income 2016 -65,6 M
Finance 2016 347 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 52,25
EV / Sales 2016 13,3x
EV / Sales 2017 9,23x
Capitalization 23 963 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 110 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith CFO, Executive VP & Principal Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-23.14%23 963
AMGEN, INC.5.24%127 850
GILEAD SCIENCES, INC.-20.45%106 233
CELGENE CORPORATION-7.65%85 728
REGENERON PHARMACEUTIC..-25.35%42 671
ACTELION LTD17.62%18 399
More Results